CPOX-related hereditary coproporphyria
diseaseOn this page
Also known as CPOX-related hepatic porphyria
Summary
CPOX-related hereditary coproporphyria (MONDO:0800180) is a disease with 1 cohort gene.
At a glance
- Cohort genes: 1
- ClinVar variants: 4
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | CPOX-related hereditary coproporphyria |
| Mondo ID | MONDO:0800180 |
| GARD | 0026471 |
| Is cancer (heuristic) | no |
Also known as: CPOX-related hepatic porphyria
Data availability: 4 ClinVar variants.
Disease family
An umbrella term covering 2 Mondo subtypes.
Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › hereditary skin disorder › hereditary photodermatosis › inherited porphyria › CPOX-related hereditary coproporphyria
Related subtypes (8): erythropoietic protoporphyria, cutaneous porphyria, porphyria due to ALA dehydratase deficiency, erythropoietic uroporphyria associated with myeloid malignancy, chester porphyria, UROD-related inherited porphyria, HMBS-related hepatic porphyria, PPOX-related hepatic porphyria
Subtypes (2): hereditary coproporphyria, harderoporphyria
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
4 retrieved; paginated sample, class counts are floors:
1 likely pathogenic, 1 conflicting classifications of pathogenicity, 1 pathogenic/likely pathogenic, 1 uncertain significance
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 453 | NM_000097.7(CPOX):c.1210A>G (p.Lys404Glu) | CPOX | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 3068558 | NM_000097.7(CPOX):c.488_509delinsAGCTGCTGATTCTGG (p.Val163fs) | CPOX | Likely pathogenic | criteria provided, single submitter |
| 346987 | NM_000097.7(CPOX):c.299A>T (p.Glu100Val) | CPOX | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 4531914 | NM_000097.7(CPOX):c.877G>C (p.Ala293Pro) | CPOX | Uncertain significance | criteria provided, single submitter |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 0 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| CPOX | Orphanet:659672 | Harderoporphyria |
| CPOX | Orphanet:79273 | Hereditary coproporphyria |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| CPOX | HGNC:2321 | ENSG00000080819 | P36551 | Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| CPOX | Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial | Catalyzes the aerobic oxidative decarboxylation of propionate groups of rings A and B of coproporphyrinogen-III to yield the vinyl groups in protoporphyrinogen-IX and participates to the sixth step in the heme biosynthetic pathway. |
Protein-family classification
Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Enzyme (other) | 1 | 12.0× | 0.083 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| CPOX | Enzyme (other) | yes | 1.3.3.3 | Coprogen_oxidase_aer, Coprogen_oxidase_CS, Coprogen_oxidase_aer_sf |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| C1 segment of cervical spinal cord | 1 |
| jejunal mucosa | 1 |
| trabecular bone tissue | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| CPOX | 268 | tissue_specific | marker | trabecular bone tissue, C1 segment of cervical spinal cord, jejunal mucosa |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| CPOX | 2,015 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| CPOX | P36551 | 1 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 1. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Heme biosynthesis | 1 | 761.3× | 0.001 | CPOX |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| response to insecticide | 1 | 2808.7× | 0.001 | CPOX |
| response to methylmercury | 1 | 2407.4× | 0.001 | CPOX |
| obsolete protoporphyrinogen IX biosynthetic process | 1 | 1685.2× | 0.001 | CPOX |
| heme B biosynthetic process | 1 | 1685.2× | 0.001 | CPOX |
| heme A biosynthetic process | 1 | 1532.0× | 0.001 | CPOX |
| response to arsenic-containing substance | 1 | 1203.7× | 0.001 | CPOX |
| response to iron ion | 1 | 936.2× | 0.001 | CPOX |
| response to lead ion | 1 | 936.2× | 0.001 | CPOX |
| heme biosynthetic process | 1 | 601.9× | 0.002 | CPOX |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| CPOX | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 1.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| CPOX | 3 | Binding:3 |
Cohort enzymes (BRENDA EC)
| Symbol | EC numbers | Names |
|---|---|---|
| CPOX | 1.3.3.3 | coproporphyrinogen oxidase |
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 1 | CPOX |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 0 |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| CPOX | 3 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: CPOX